What was the primary comparison evaluated in this exploratory analysis of the ALTTO study?
Trastuzumab versus lapatinib in HER2-positive disease
Aromatase inhibitors (AI) versus tamoxifen in hormone receptor-positive/HER2-positive disease
Ovarian function suppression versus tamoxifen alone in premenopausal patients